Literature DB >> 14578270

Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes.

Suzy Y Honisett, Lily Stojanovska, Krishnankutty Sudhir, Bronwyn A Kingwell, Tye Dawood, Paul A Komesaroff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14578270     DOI： 10.2337/diacare.26.11.3194

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  4 in total

Review 1.  Rosiglitazone/Metformin.

Authors:  Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  A meta-analysis of the effect of thiazolidinediones on blood pressure.

Authors:  Rehan Qayyum; Jurga Adomaityte
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

3.  Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.

Authors:  Jacob D Peuler; Laura E Phelps
Journal:  J Smooth Muscle Res       Date:  2015

4.  Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).

Authors:  Michel Komajda; Paula Curtis; Markolf Hanefeld; Henning Beck-Nielsen; Stuart J Pocock; Andrew Zambanini; Nigel P Jones; Ramon Gomis; Philip D Home
Journal:  Cardiovasc Diabetol       Date:  2008-04-24       Impact factor: 9.951
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.